Proteasome-targeted nanobodies alleviate pathology and functional decline in an a-synuclein-based Parkinson's disease model.
Proteasome-targeted nanobodies alleviate pathology and functional decline in an a-synuclein-based Parkinson's disease model. NPJ Parkinsons Dis. 2018; 4:25.